S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The Next Big Crisis Is Here (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The Next Big Crisis Is Here (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The Next Big Crisis Is Here (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The Next Big Crisis Is Here (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
NASDAQ:OPTN

OptiNose - OPTN Stock Forecast, Price & News

$1.73
-0.01 (-0.57%)
(As of 01/26/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.65
▼
$1.76
50-Day Range
$1.68
▼
$1.92
52-Week Range
$1.60
▼
$4.30
Volume
72,235 shs
Average Volume
117,374 shs
Market Capitalization
$144.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.67

OptiNose MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
169.7% Upside
$4.67 Price Target
Short Interest
Bearish
3.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.10
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$93,924 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.86) to ($0.49) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

213th out of 1,048 stocks

Pharmaceutical Preparations Industry

96th out of 513 stocks

See Top Rated MarketRank™ Stocks Here

OPTN stock logo

About OptiNose (NASDAQ:OPTN) Stock

OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.

Receive OPTN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter.

OPTN Stock News Headlines

January 19, 2023 | americanbankingnews.com
Peter K. Miller Sells 29,664 Shares of OptiNose, Inc. (NASDAQ:OPTN) Stock
December 27, 2022 | finance.yahoo.com
OptiNose, Inc.'s (NASDAQ:OPTN) top owners are private equity firms with 37% stake, while33% is held by institutions
January 27, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
December 15, 2022 | finance.yahoo.com
Optinose Appoints Paul Spence as Chief Commercial Officer
December 9, 2022 | finance.yahoo.com
Optinose Announces Departure of Acting Chief Financial Officer
November 30, 2022 | finance.yahoo.com
Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference
November 22, 2022 | finance.yahoo.com
Bucks County health care company expects to raise $50M
November 21, 2022 | finance.yahoo.com
Optinose Announces Pricing of Public Offering of Common Stock and Warrants
January 27, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
November 21, 2022 | finance.yahoo.com
Optinose Announces Proposed Public Offering of Common Stock and Warrants
November 16, 2022 | finance.yahoo.com
Analysts Are More Bearish On OptiNose, Inc. (NASDAQ:OPTN) Than They Used To Be
November 12, 2022 | finance.yahoo.com
OptiNose Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
November 10, 2022 | finance.yahoo.com
OptiNose (OPTN) Reports Q3 Loss, Misses Revenue Estimates
November 9, 2022 | finance.yahoo.com
Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting
November 8, 2022 | finance.yahoo.com
Optinose Announces Reporting Date for Third Quarter 2022 Financial Results
October 16, 2022 | finance.yahoo.com
Shareholders in OptiNose (NASDAQ:OPTN) are in the red if they invested five years ago - Yahoo Finance
October 16, 2022 | finance.yahoo.com
Shareholders in OptiNose (NASDAQ:OPTN) are in the red if they invested five years ago
September 30, 2022 | finance.yahoo.com
Nasal Polyps Treatment Global Market Report 2022 - Yahoo Finance
September 23, 2022 | bizjournals.com
Soaring 76 rankings 2022: Greater Philadelphia's fastest-growing companies, Nos. 26-50 - The Business Journals
September 21, 2022 | nasdaq.com
A few OptiNose, Inc. (NASDAQ:OPTN) insiders sold shares in the last 12 months: Not a good sign for shareholders
September 19, 2022 | finance.yahoo.com
When Can We Expect A Profit From OptiNose, Inc. (NASDAQ:OPTN)? - Yahoo Finance
September 18, 2022 | finance.yahoo.com
When Can We Expect A Profit From OptiNose, Inc. (NASDAQ:OPTN)?
September 16, 2022 | reuters.com
OPTN.O - OptiNose Inc | Stock Price & Latest News | Reuters
September 15, 2022 | globenewswire.com
Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors - GlobeNewswire
September 12, 2022 | businesswire.com
Sinusitis Drug Pipeline Insight Report 2022: Pipeline Analysis, Therapeutic Assessment, Unmet Needs, & Impact of Drugs - ResearchAndMarkets.com - Business Wire
September 7, 2022 | finance.yahoo.com
Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting - Yahoo Finance
September 6, 2022 | globenewswire.com
Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting - GlobeNewswire
See More Headlines
Receive OPTN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter.

OPTN Company Calendar

Last Earnings
11/10/2022
Today
1/27/2023
Next Earnings (Estimated)
3/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OPTN
CUSIP
N/A
CIK
1494650
Web
www.optinose.com
Phone
(267) 364-3500
Fax
N/A
Employees
189
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.67
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+169.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.95)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-82,300,000.00
Net Margins
-96.64%
Pretax Margin
-96.64%
Return on Equity
N/A
Return on Assets
-57.05%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.57
Quick Ratio
0.51

Sales & Book Value

Annual Sales
$74.65 million
Price / Sales
1.94
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.26) per share
Price / Book
-6.65

Miscellaneous

Outstanding Shares
83,520,000
Free Float
79,511,000
Market Cap
$144.49 million
Optionable
Not Optionable
Beta
-0.24

Key Executives

  • Peter Kaighn Miller
    Chief Executive Officer & Director
  • Ramy A. MahmoudRamy A. Mahmoud
    President & Chief Operating Officer
  • John C. Messina
    SVP-Clinical Development & Medical Affairs
  • Michael C. Berkey
    Vice President-Technical Operations
  • Harry Sacks
    VP-Medical Affairs & Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













OPTN Stock - Frequently Asked Questions

Should I buy or sell OptiNose stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OPTN shares.
View OPTN analyst ratings or view top-rated stocks.

What is OptiNose's stock price forecast for 2023?

2 brokerages have issued 1 year price targets for OptiNose's stock. Their OPTN share price forecasts range from $4.00 to $5.00. On average, they predict the company's stock price to reach $4.67 in the next twelve months. This suggests a possible upside of 169.7% from the stock's current price.
View analysts price targets for OPTN or view top-rated stocks among Wall Street analysts.

How have OPTN shares performed in 2023?

OptiNose's stock was trading at $1.85 at the beginning of 2023. Since then, OPTN shares have decreased by 6.5% and is now trading at $1.73.
View the best growth stocks for 2023 here.

When is OptiNose's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our OPTN earnings forecast.

How were OptiNose's earnings last quarter?

OptiNose, Inc. (NASDAQ:OPTN) posted its quarterly earnings results on Thursday, November, 10th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.01. The business had revenue of $20.08 million for the quarter, compared to analysts' expectations of $24.20 million.

What guidance has OptiNose issued on next quarter's earnings?

OptiNose updated its FY 2022 earnings guidance on Sunday, December, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $74.00 million-$78.00 million, compared to the consensus revenue estimate of $79.87 million.

What other stocks do shareholders of OptiNose own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Proteostasis Therapeutics (PTI), Idera Pharmaceuticals (IDRA), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Selecta Biosciences (SELB), VBI Vaccines (VBIV), Strongbridge Biopharma (SBBP) and SCYNEXIS (SCYX).

When did OptiNose IPO?

(OPTN) raised $101 million in an initial public offering on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.

What is OptiNose's stock symbol?

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

How do I buy shares of OptiNose?

Shares of OPTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OptiNose's stock price today?

One share of OPTN stock can currently be purchased for approximately $1.73.

How much money does OptiNose make?

OptiNose (NASDAQ:OPTN) has a market capitalization of $144.49 million and generates $74.65 million in revenue each year. The company earns $-82,300,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

How many employees does OptiNose have?

The company employs 189 workers across the globe.

How can I contact OptiNose?

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The official website for the company is www.optinose.com. The company can be reached via phone at (267) 364-3500 or via email at investors@optinose.com.

This page (NASDAQ:OPTN) was last updated on 1/27/2023 by MarketBeat.com Staff